Genomic Heterogeneity of ALK Fusion Breakpoints in Non-Small-Cell Lung

Total Page:16

File Type:pdf, Size:1020Kb

Genomic Heterogeneity of ALK Fusion Breakpoints in Non-Small-Cell Lung Modern Pathology (2018) 31, 791–808 © 2018 USCAP, Inc All rights reserved 0893-3952/18 $32.00 791 Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer Jason N Rosenbaum1, Ryan Bloom2, Jason T Forys3, Jeff Hiken3, Jon R Armstrong3, Julie Branson4, Samantha McNulty4, Priya D Velu1, Kymberlie Pepin5, Haley Abel6, Catherine E Cottrell7, John D Pfeifer4, Shashikant Kulkarni8, Ramaswamy Govindan5, Eric Q Konnick9, Christina M Lockwood9 and Eric J Duncavage4 1Department of Pathology and Laboratory Medicine, University of Pennsylvania, The University of Pennsylvania Center for Personalized Diagnostics, Philadelphia, PA, USA; 2Unum Therapeutics, Cambridge, MA, USA; 3Cofactor Genomics, St Louis, MO, USA; 4Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine, St Louis, MO, USA; 5Department of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, USA; 6McDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA; 7Nationwide Children’s Hospital, Institute for Genomic Medicine, Columbus, OH, USA; 8Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA and 9Department of Laboratory Medicine, University of Washington, Seattle, WA, USA In lung adenocarcinoma, canonical EML4-ALK inversion results in a fusion protein with a constitutively active ALK kinase domain. Evidence of ALK rearrangement occurs in a minority (2–7%) of lung adenocarcinoma, and only ~ 60% of these patients will respond to targeted ALK inhibition by drugs such as crizotinib and ceritinib. Clinically, targeted anti-ALK therapy is often initiated based on evidence of an ALK genomic rearrangement detected by fluorescence in situ hybridization (FISH) of interphase cells in formalin-fixed, paraffin-embedded tissue sections. At the genomic level, however, ALK rearrangements are heterogeneous, with multiple potential breakpoints in EML4, and alternate fusion partners. Using next-generation sequencing of DNA and RNA together with ALK immunohistochemistry, we comprehensively characterized genomic breakpoints in 33 FISH-positive lung adenocarcinomas. Of these 33 cases, 29 (88%) had detectable DNA level ALK rearrangements involving EML4, KIF5B, or non-canonical partners including ASXL2, ATP6V1B1, PRKAR1A, and SPDYA. A subset of 12 cases had material available for RNA-Seq. Of these, eight of eight (100%) cases with DNA rearrangements showed ALK fusion transcripts from RNA-Seq; three of four cases (75%) without detectable DNA rearrangements were similarly negative by RNA-Seq, and one case was positive by RNA-Seq but negative by DNA next- generation sequencing. By immunohistochemistry, 17 of 19 (89%) tested cases were clearly positive for ALK protein expression; the remaining cases had no detectable DNA level rearrangement or had a non-canonical rearrangement not predicted to form a fusion protein. Survival analysis of patients treated with targeted ALK inhibitors demonstrates a significant difference in mean survival between patients with next-generation sequencing confirmed EML4-ALK rearrangements, and those without (20.6 months vs 5.4 months, Po0.01). Together, these data demonstrate abundant genomic heterogeneity among ALK-rearranged lung adenocarci- noma, which may account for differences in treatment response with targeted ALK inhibitors. Modern Pathology (2018) 31, 791–808; doi:10.1038/modpathol.2017.181; published online 12 January 2018 Cancer accounted for 8.8 million deaths in 2015, five (1.69 million) of those deaths, making it the with lung cancer comprising approximately one in leading cause of cancer mortality worldwide.1 The anticipated number of new cases of lung and bronchial cancer in the United States for 2017 is 2 Correspondence: Dr JN Rosenbaum, MD, Department of Pathology 222 500 with 155 870 deaths. The 5-year survival and Laboratory Medicine, University of Pennsylvania, The rate of lung cancer from 2006 to 2012 in the United University of Pennsylvania Center for Personalized Diagnostics, States was 18% (15% for men and 21% for women). 3020 Market Street Ste. 220, Philadelphia, PA 19104, USA. E-mail: [email protected] The treatment and prognosis of lung cancer varies Received 12 June 2017; revised 24 October 2017; accepted 26 considerably based on the specific pathologic find- October 2017; published online 12 January 2018 ings and subtype. Broadly, lung cancer is divided www.modernpathology.org Genomic heterogeneity of ALK fusions 792 JN Rosenbaum et al into small-cell lung cancer that is aggressive (though however, the partner breakpoint within EML4 is sensitive to treatment with radiation), and non- quite variable, occurring in a variety of introns, most small-cell lung cancer that can show a range of commonly intron 13, 20, and 6 (reference sequence behaviors and treatments dependent on other prop- NM_019063.4).4 Other ALK translocation partners erties of the tumor, including molecular alterations. (the most common of which is KIF5B) constitute a Non-small-cell lung cancer itself is divided into small but significant proportion of ALK rearrange- squamous carcinoma and adenocarcinoma. In lung ments in lung adenocarcinoma, and new rearrange- adenocarcinoma, the canonical EML4-ALK inversion ment partners are reported regularly.7,21–31 The results in a fusion protein containing a dysregulated, tumorigenic properties of ALK fusion proteins derive constitutively active ALK kinase domain.3–8 from constitutive activity of the tyrosine kinase Although evidence of ALK rearrangement only domain of ALK. The 5′ fusion partner provides occurs in a minority (2–7%) of cases,9 ~ 60% will promoter and initiation sites, and permits constitu- respond to targeted inhibition of ALK by drugs such tive dimerization of the translated protein.3,7,32 The as crizotinib, ceritinib, alectinib, and brigatinib.10–17 canonical EML4-ALK rearrangement is well estab- ALK rearrangement is associated with specific lished as a driver of cancer, and limited data suggest clinical features, including higher incidence among that different rearrangements may vary in their women, younger patients, patients of Asian descent, pathogenic properties, even among the canonical and non-smokers. Moreover, there are a handful of fusions.33–35 In addition, single-nucleotide variants histo- and cyto-pathologic features associated with (SNVs) altering the coding sequence of ALK or other ALK rearrangement (acinar structure, higher histolo- genes (such as EGFR) can drive oncogenesis or gic grade).18–20 None of these features (alone or in impart resistance to targeted inhibition, despite the combination) provide a strong enough association to presence of an ALK rearrangement.36–46 diagnose the chromosomal rearrangement or select Clinically, targeted anti-ALK therapy is initiated patients for testing, however, and ancillary diagnos- based on evidence of ALK genomic rearrangement as tic tests remain critical for identifying the therapeu- detected by fluorescence in situ hybridization (FISH) tic target. performed on interphase cells in formalin-fixed, The canonical ALK rearrangement in lung adeno- paraffin-embedded tissue sections. Because of the carcinoma is an inversion of the short (p) arm of promiscuous nature of the translocation, a ‘break- chromosome 2, with breakpoints in the ALK and apart’ FISH probe is the preferred identification EML4 genes (Figure 1). The ALK breakpoint lies most strategy, forming the basis for the original ‘in vitro frequently within intron 19 (reference sequence device companion diagnostic’ (CDx) assay approved NM_004304.4), though there are rare exceptions; by the US-FDA.47,48 Although break-apart FISH Figure 1 Inversion of chromosome 2p results in constitutively active EML4-ALK fusion protein. Structural rearrangements involving the ALK gene drive a number of cancers. In non-small-cell lung cancer, the most common structural rearrangement involving the ALK locus is an inversion of a portion of chromosome 2p, juxtaposing the 5′ portion of EML4 to the 3′ portion of ALK (a). ALK is not normally transcribed in adult lung, but under the control of the EML4 promoter, the EML4-ALK fusion gene is transcribed. Notably, the reciprocal translocation juxtaposing the 5′ portion of ALK to the 3′ portion of EML4 also occurs, but as it retains the ALK promoter, it is not transcribed (indicated in gray). Wild-type ALK is a receptor tyrosine kinase known to drive developmental pathways, particularly in the nervous system (tyrosine kinase domain indicated by dark-green bars). In the presence of ALK ligand, wild-type ALK proteins homodimerize, driving downstream developmental processes such as cellular proliferation (b). Under transcriptional control of the EML4 promoter, the EML4-ALK fusion protein is expressed in lung tissue, and the dimerization domain of EML4 (dark purple bars) permits unregulated dimerization of the TK domain, constitutively activating downstream pathways. Modern Pathology (2018) 31, 791–808 Genomic heterogeneity of ALK fusions JN Rosenbaum et al 793 probes are generally considered sensitive, they do has recently become available in the clinical setting not permit differentiation or identification of ALK and can be performed on routine formalin-fixed, partner genes or non-canonical breakpoints, raising paraffin-embedded material. For fusion detection, a the possibility that not all aberrant ALK FISH major advantage of RNA-Seq over targeted DNA- patterns (among
Recommended publications
  • Hares, K. M., Miners, S., Scolding, N
    Hares, K. M. , Miners, S., Scolding, N., Love, S., & Wilkins, A. (2019). KIF5A and KLC1 expression in Alzheimer’s disease: relationship and genetic influences. AMRC Open Research, 1, [1]. https://doi.org/10.12688/amrcopenres.12861.1 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.12688/amrcopenres.12861.1 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via F1000 Research at https://amrcopenresearch.org/articles/1-1/v1 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ AMRC Open Research AMRC Open Research 2019, 1:1 Last updated: 11 APR 2019 RESEARCH ARTICLE KIF5A and KLC1 expression in Alzheimer’s disease: relationship and genetic influences [version 1; peer review: 1 approved, 1 approved with reservations, 1 not approved] Kelly Hares 1, Scott Miners2, Neil Scolding1, Seth Love2, Alastair Wilkins1 1Bristol Medical School: Translational Health Sciences, MS and Stem Cell Group, University of Bristol, Bristol, BS10 5NB, UK 2Bristol Medical School: Translational Health Sciences, Dementia Research Group, University of Bristol, Bristol, BS10 5NB, UK First published: 19 Feb 2019, 1:1 (https://doi.org/10.12688/amrcopenres.12861.1 Open Peer Review v1 ) Latest published: 19 Feb 2019, 1:1 ( https://doi.org/10.12688/amrcopenres.12861.1) Referee Status: Abstract Invited Referees Background: Early disturbances in axonal transport, before the onset of gross 1 2 3 neuropathology, occur in a spectrum of neurodegenerative diseases including Alzheimer’s disease.
    [Show full text]
  • CDKN1B-Y88 Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap20721b
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CDKN1B-Y88 Antibody Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP20721b Specification CDKN1B-Y88 Antibody - Product Information Application WB,E Primary Accession P46527 Other Accession Q60439 Reactivity Human Predicted Hamster Host Rabbit Clonality Polyclonal Isotype Rabbit IgG CDKN1B-Y88 Antibody - Additional Information Gene ID 1027 Other Names Cyclin-dependent kinase inhibitor 1B, Cyclin-dependent kinase inhibitor p27, Western blot analysis of lysate from MCF-7 p27Kip1, CDKN1B, KIP1 cell line, using CDKN1B-Y88 (Cat. #AP20721b). AP20721b was diluted at Target/Specificity 1:1000. A goat anti-rabbit IgG H&L(HRP) at This antibody is generated from a rabbit 1:5000 dilution was used as the secondary immunized with a KLH conjugated synthetic antibody. Lysate at 35ug. peptide between 81-113 amino acids from human. CDKN1B-Y88 Antibody - Background Dilution WB~~1:1000 Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin Format E- and cyclin A-CDK2 complexes. Forms a Purified polyclonal antibody supplied in PBS complex with cyclin type D-CDK4 complexes with 0.09% (W/V) sodium azide. This antibody is purified through a protein A and is involved in the assembly, stability, and column, followed by peptide affinity modulation of CCND1- CDK4 complex purification. activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes Storage depending on its phosphorylation state and/or Maintain refrigerated at 2-8°C for up to 2 stoichometry. weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw CDKN1B-Y88 Antibody - References cycles.
    [Show full text]
  • Replace This with the Actual Title Using All Caps
    UNDERSTANDING THE GENETICS UNDERLYING MASTITIS USING A MULTI-PRONGED APPROACH A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Asha Marie Miles December 2019 © 2019 Asha Marie Miles UNDERSTANDING THE GENETICS UNDERLYING MASTITIS USING A MULTI-PRONGED APPROACH Asha Marie Miles, Ph. D. Cornell University 2019 This dissertation addresses deficiencies in the existing genetic characterization of mastitis due to granddaughter study designs and selection strategies based primarily on lactation average somatic cell score (SCS). Composite milk samples were collected across 6 sampling periods representing key lactation stages: 0-1 day in milk (DIM), 3- 5 DIM, 10-14 DIM, 50-60 DIM, 90-110 DIM, and 210-230 DIM. Cows were scored for front and rear teat length, width, end shape, and placement, fore udder attachment, udder cleft, udder depth, rear udder height, and rear udder width. Independent multivariable logistic regression models were used to generate odds ratios for elevated SCC (≥ 200,000 cells/ml) and farm-diagnosed clinical mastitis. Within our study cohort, loose fore udder attachment, flat teat ends, low rear udder height, and wide rear teats were associated with increased odds of mastitis. Principal component analysis was performed on these traits to create a single new phenotype describing mastitis susceptibility based on these high-risk phenotypes. Cows (N = 471) were genotyped on the Illumina BovineHD 777K SNP chip and considering all 14 traits of interest, a total of 56 genome-wide associations (GWA) were performed and 28 significantly associated quantitative trait loci (QTL) were identified.
    [Show full text]
  • Drp1 Overexpression Induces Desmin Disassembling and Drives Kinesin-1 Activation Promoting Mitochondrial Trafficking in Skeletal Muscle
    Cell Death & Differentiation (2020) 27:2383–2401 https://doi.org/10.1038/s41418-020-0510-7 ARTICLE Drp1 overexpression induces desmin disassembling and drives kinesin-1 activation promoting mitochondrial trafficking in skeletal muscle 1 1 2 2 2 3 Matteo Giovarelli ● Silvia Zecchini ● Emanuele Martini ● Massimiliano Garrè ● Sara Barozzi ● Michela Ripolone ● 3 1 4 1 5 Laura Napoli ● Marco Coazzoli ● Chiara Vantaggiato ● Paulina Roux-Biejat ● Davide Cervia ● 1 1 2 1,4 6 Claudia Moscheni ● Cristiana Perrotta ● Dario Parazzoli ● Emilio Clementi ● Clara De Palma Received: 1 August 2019 / Revised: 13 December 2019 / Accepted: 23 January 2020 / Published online: 10 February 2020 © The Author(s) 2020. This article is published with open access Abstract Mitochondria change distribution across cells following a variety of pathophysiological stimuli. The mechanisms presiding over this redistribution are yet undefined. In a murine model overexpressing Drp1 specifically in skeletal muscle, we find marked mitochondria repositioning in muscle fibres and we demonstrate that Drp1 is involved in this process. Drp1 binds KLC1 and enhances microtubule-dependent transport of mitochondria. Drp1-KLC1 coupling triggers the displacement of KIF5B from 1234567890();,: 1234567890();,: kinesin-1 complex increasing its binding to microtubule tracks and mitochondrial transport. High levels of Drp1 exacerbate this mechanism leading to the repositioning of mitochondria closer to nuclei. The reduction of Drp1 levels decreases kinesin-1 activation and induces the partial recovery of mitochondrial distribution. Drp1 overexpression is also associated with higher cyclin-dependent kinase-1 (Cdk-1) activation that promotes the persistent phosphorylation of desmin at Ser-31 and its disassembling. Fission inhibition has a positive effect on desmin Ser-31 phosphorylation, regardless of Cdk-1 activation, suggesting that induction of both fission and Cdk-1 are required for desmin collapse.
    [Show full text]
  • Understanding the Role of the Chromosome 15Q25.1 in COPD Through Epigenetics and Transcriptomics
    European Journal of Human Genetics (2018) 26:709–722 https://doi.org/10.1038/s41431-017-0089-8 ARTICLE Understanding the role of the chromosome 15q25.1 in COPD through epigenetics and transcriptomics 1 1,2 1,3,4 5,6 5,6 Ivana Nedeljkovic ● Elena Carnero-Montoro ● Lies Lahousse ● Diana A. van der Plaat ● Kim de Jong ● 5,6 5,7 6 8 9 10 Judith M. Vonk ● Cleo C. van Diemen ● Alen Faiz ● Maarten van den Berge ● Ma’en Obeidat ● Yohan Bossé ● 11 1,12 12 1 David C. Nickle ● BIOS Consortium ● Andre G. Uitterlinden ● Joyce J. B. van Meurs ● Bruno C. H. Stricker ● 1,4,13 6,8 5,6 1 1 Guy G. Brusselle ● Dirkje S. Postma ● H. Marike Boezen ● Cornelia M. van Duijn ● Najaf Amin Received: 14 March 2017 / Revised: 6 November 2017 / Accepted: 19 December 2017 / Published online: 8 February 2018 © The Author(s) 2018. This article is published with open access Abstract Chronic obstructive pulmonary disease (COPD) is a major health burden in adults and cigarette smoking is considered the most important environmental risk factor of COPD. Chromosome 15q25.1 locus is associated with both COPD and smoking. Our study aims at understanding the mechanism underlying the association of chromosome 15q25.1 with COPD through epigenetic and transcriptional variation in a population-based setting. To assess if COPD-associated variants in 1234567890();,: 15q25.1 are methylation quantitative trait loci, epigenome-wide association analysis of four genetic variants, previously associated with COPD (P < 5 × 10−8) in the 15q25.1 locus (rs12914385:C>T-CHRNA3, rs8034191:T>C-HYKK, rs13180: C>T-IREB2 and rs8042238:C>T-IREB2), was performed in the Rotterdam study (n = 1489).
    [Show full text]
  • 1 Supporting Information for a Microrna Network Regulates
    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
    [Show full text]
  • VU Research Portal
    VU Research Portal Genetic architecture and behavioral analysis of attention and impulsivity Loos, M. 2012 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Loos, M. (2012). Genetic architecture and behavioral analysis of attention and impulsivity. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 28. Sep. 2021 Genetic architecture and behavioral analysis of attention and impulsivity Maarten Loos 1 About the thesis The work described in this thesis was performed at the Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University, Amsterdam, The Netherlands. This work was in part funded by the Dutch Neuro-Bsik Mouse Phenomics consortium. The Neuro-Bsik Mouse Phenomics consortium was supported by grant BSIK 03053 from SenterNovem (The Netherlands).
    [Show full text]
  • Integrative Genomics Discoveries and Development at the Center for Applied Genomics at CHOP
    The Children’s Hospital of Philadelphia Integrative Genomics Discoveries and Development at The Center for Applied Genomics at CHOP Novel Genome-based Therapeutic Approaches Hakon Hakonarson, MD, PhD, Professor of Pediatrics CHOP’s Endowed Chair in Genetic Research Director, Center for Applied Genomics The Children’s Hospital of Philadelphia University of Pennsylvania, School of Medicine Duke Center for Applied Genomics and Precision Medicine 2019 Genomic and Precision Medicine Forum Nov 07, 2019 Genomics in the 21st Century Disclosures Dr. Hakonarson and CHOP own stock in Aevi Genomic Medicine Inc. developing anti-LIGHT therapy for IBD. Dr. Hakonarson is an inventor of technology involving therapeutic development of ADHD, GLA and HCCAA Novel Therapeutic Stem Cell/Gene Editing Approaches § iPS and stem cell therapy shows early promise § Gene therapy for LCA (RPE65) at CHOP via AAV § Targeted T cell therapy for cancer (UPENN/CHOP) § CRISPR-cas9 gene editing § Single cell sequencing The Center for Applied Genomics (CAG) at CHOP u Founded in June 2006 u Staff of 70 u Over 100 active disease projects with CHOP/Penn collaborators u TARGET: Genotype 100,000 children u ~450k GWAS samples >130k kids u IC - participation in future studies >85% u Database u Electronic Health Records u extensive information on each child u >1.2 million visits per year to Population Genomics Research CHOP Recruitment of CHOP/PENN HealthCare Network Patients u High-level of automation ADHD, Autism, Diabetes, IBD, Autoimmunity, Asthma/Atopy, Cancer, RDs - all high priority
    [Show full text]
  • Extensive Expansion of the Speedy Gene Family in Homininae and Functional Differentiation in Humans
    bioRxiv preprint doi: https://doi.org/10.1101/354886; this version posted June 26, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Extensive Expansion of the Speedy gene Family in Homininae and Functional Differentiation in Humans Liang Wang1,2†, Hui Wang1,3,4†, Hongmei Wang1,Yuhui Zhao2, Xiaojun Liu1, Gary Wong5, Qinong Ye6, Xiaoqin Xia7, George F. Gao2, Shan Gao1,8,* 1CAS Key Laboratory of Bio-medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China; 2CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; 3 Institute of Biomedical Engineering, Department of Engineering Science, Old Road Campus Research Building, University of Oxford, Oxford OX3 7DQ, UK; 4Oxford Suzhou Centre for Advanced Research (OSCAR), 388 Ruo Shui Road, Suzhou Industrial Park, Jiangsu 215123, China; 5Shenzhen Key Laboratory of Pathogen and Immunity, Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen 518112, China; 6Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing 100850, China; 7Institutes of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei, P. R. China, 430072; 8Medical College, Guizhou University, District of Huaxi, Guiyang 550025, China. †These authors contributed equally to this work 1 bioRxiv preprint doi: https://doi.org/10.1101/354886; this version posted June 26, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Structural Basis for Isoform-Specific Kinesin-1 Recognition of Y-Acidic
    bioRxiv preprint doi: https://doi.org/10.1101/322057; this version posted May 14, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Structural basis for isoform-specific kinesin-1 recognition of Y-acidic cargo adaptors Stefano Pernigo1, Magda Chegkazi1, Yan Y. Yip1, Conor Treacy1, Giulia Glorani1, Kjetil Hansen2, Argyris Politis2, Mark P. Dodding1,3,*, Roberto A. Steiner1,* 1Randall Centre of Cell and Molecular Biophysics, Faculty of Life Sciences and Medicine, King’s College London, London SE1 1UL, UK 2Department of Chemistry, King’s College London Britannia House 7 Trinity Street, London, SE1 1DB (UK) 3current address School of Biochemistry, Faculty of Biomedical Sciences, University of Bristol, University Walk, Bristol BS8 1TD *Correspondence email: [email protected] or [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/322057; this version posted May 14, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The light chains (KLCs) of the heterotetrameric microtubule motor kinesin-1, that bind to cargo adaptor proteins and regulate its activity, have a capacity to recognize short peptides via their tetratricopeptide repeat domains (KLCTPR). Here, using X-ray crystallography, we show how kinesin-1 recognizes a novel class of adaptor motifs that we call ‘Y-acidic’ (tyrosine flanked by acidic residues), in a KLC-isoform specific manner. Binding specificities of Y-acidic motifs (present in JIP1 and in TorsinA) to KLC1TPR are distinct from those utilized for the recognition of W-acidic motifs found in adaptors that are KLC- isoform non-selective.
    [Show full text]
  • "The Genecards Suite: from Gene Data Mining to Disease Genome Sequence Analyses". In: Current Protocols in Bioinformat
    The GeneCards Suite: From Gene Data UNIT 1.30 Mining to Disease Genome Sequence Analyses Gil Stelzer,1,5 Naomi Rosen,1,5 Inbar Plaschkes,1,2 Shahar Zimmerman,1 Michal Twik,1 Simon Fishilevich,1 Tsippi Iny Stein,1 Ron Nudel,1 Iris Lieder,2 Yaron Mazor,2 Sergey Kaplan,2 Dvir Dahary,2,4 David Warshawsky,3 Yaron Guan-Golan,3 Asher Kohn,3 Noa Rappaport,1 Marilyn Safran,1 and Doron Lancet1,6 1Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel 2LifeMap Sciences Ltd., Tel Aviv, Israel 3LifeMap Sciences Inc., Marshfield, Massachusetts 4Toldot Genetics Ltd., Hod Hasharon, Israel 5These authors contributed equally to the paper 6Corresponding author GeneCards, the human gene compendium, enables researchers to effectively navigate and inter-relate the wide universe of human genes, diseases, variants, proteins, cells, and biological pathways. Our recently launched Version 4 has a revamped infrastructure facilitating faster data updates, better-targeted data queries, and friendlier user experience. It also provides a stronger foundation for the GeneCards suite of companion databases and analysis tools. Improved data unification includes gene-disease links via MalaCards and merged biological pathways via PathCards, as well as drug information and proteome expression. VarElect, another suite member, is a phenotype prioritizer for next-generation sequencing, leveraging the GeneCards and MalaCards knowledgebase. It au- tomatically infers direct and indirect scored associations between hundreds or even thousands of variant-containing genes and disease phenotype terms. Var- Elect’s capabilities, either independently or within TGex, our comprehensive variant analysis pipeline, help prepare for the challenge of clinical projects that involve thousands of exome/genome NGS analyses.
    [Show full text]
  • ALK Gene ALK Receptor Tyrosine Kinase
    ALK gene ALK receptor tyrosine kinase Normal Function The ALK gene provides instructions for making a protein called ALK receptor tyrosine kinase, which is part of a family of proteins called receptor tyrosine kinases (RTKs). Receptor tyrosine kinases transmit signals from the cell surface into the cell through a process called signal transduction. The process begins when the kinase is stimulated at the cell surface and then attaches to a similar kinase (dimerizes). After dimerization, the kinase is tagged with a marker called a phosphate group (a cluster of oxygen and phosphorus atoms) in a process called phosphorylation. Phosphorylation turns on ( activates) the kinase. The activated kinase is able to transfer a phosphate group to another protein inside the cell, which is activated as a result. The activation continues through a series of proteins in a signaling pathway. These signaling pathways are important in many cellular processes such as cell growth and division (proliferation) or maturation (differentiation). Although the specific function of ALK receptor tyrosine kinase is unknown, it is thought to act early in development to help regulate the proliferation of nerve cells. Health Conditions Related to Genetic Changes Neuroblastoma At least 16 mutations in the ALK gene have been identified in some people with neuroblastoma, a type of cancerous tumor composed of immature nerve cells ( neuroblasts). Neuroblastoma and other cancers occur when a buildup of genetic mutations in critical genes—those that control cell proliferation or differentiation—allows cells to grow and divide uncontrollably to form a tumor. In most cases, these genetic changes are acquired during a person's lifetime and are called somatic mutations.
    [Show full text]